Satiating Diet, Appetite Control and Body Weight Loss in Individuals With Obesity
Launched by LAVAL UNIVERSITY · Dec 1, 2021
Trial Information
Current as of May 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying different ways to help people with obesity control their appetite and maintain weight loss. Specifically, it looks at whether a non-restrictive diet—meaning you don't have to count calories or limit food intake—can help people feel full, lose weight, and keep it off over time. The trial will last 18 months and include three groups: one group will follow the non-restrictive diet for the entire time, another will start with a traditional calorie-restricted diet and then switch to the non-restrictive diet, and the third group will follow basic healthy eating guidelines. Throughout the study, participants will receive support from a dietitian and will be monitored for their eating habits, physical activity, and overall health.
To join this trial, participants need to be between 18 and 50 years old, have a body mass index (BMI) of 30 to 40, and meet specific waist size measurements (over 102 cm for men and over 88 cm for women). However, those taking certain medications, experiencing significant weight changes recently, or with specific health issues won’t be eligible. Participants can expect regular check-ins with a dietitian, guidance on preparing satisfying meals, and encouragement to stay active. This study aims to provide insights into effective weight management strategies for individuals living with obesity.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • individuals with a BMI ≥30 and \<40 kg/m2
- • aged between 18-50 years
- • waist circumference \>102 cm in men and \>88 cm in women.
- Exclusion Criteria:
- • taking medications that could influence appetite or body weight (e.g. thyroid replacement therapy, sulfonylureas and glucocorticoids)
- • being treated with insulin for type 2 diabetes
- • large body weight fluctuations (\>4 kg over last two months)
- • characterized by high restraint behaviour (score \>12, measured with the TFEQ)
- • history of an eating disorder (e.g. binge eating disorder) using the EDE questionnaire
- • performing \>150 min of moderate-vigorous intensity physical activity/week
- • use of nutritional supplements (multivitamins, calcium, protein, fibre); 8) smoking, drugs or alcohol (\>2 drinks/d)
- • consumption of \>5 cups of coffee/d
- • (pre)menopausal or pregnant women
- • diagnosis of chronic diseases, acute infections or gastric problems (e.g. ulcers)
- • food allergies/intolerances to ingredients/foods in the satiating intervention
- • having a pacemaker (for fMRI)
- • taking sedatives or sleeping pills
- • symptoms of depression (\>20 on the BDI).
About Laval University
Laval University is a prestigious research institution located in Quebec, Canada, renowned for its commitment to advancing knowledge and innovation in various fields, including health sciences. The university actively engages in clinical trials aimed at exploring new therapeutic interventions and improving patient outcomes. With a strong emphasis on ethical standards and rigorous scientific methodologies, Laval University collaborates with multidisciplinary teams of researchers, healthcare professionals, and industry partners to conduct high-quality clinical research. Its state-of-the-art facilities and dedication to fostering a culture of inquiry position Laval University as a leader in clinical research, contributing significantly to the understanding and treatment of diverse medical conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Québec, Quebec, Canada
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials